These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

165 related articles for article (PubMed ID: 31322098)

  • 1. Baseline Decrement in Patients with Mild Myasthenia Gravis Predicts Immunomodulation Treatment.
    Abraham A; Lovblom LE; Bril V
    Can J Neurol Sci; 2019 Nov; 46(6):762-766. PubMed ID: 31322098
    [TBL] [Abstract][Full Text] [Related]  

  • 2. IVIG and PLEX in the treatment of myasthenia gravis.
    Bril V; Barnett-Tapia C; Barth D; Katzberg HD
    Ann N Y Acad Sci; 2012 Dec; 1275():1-6. PubMed ID: 23278570
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Electrophysiological testing is correlated with myasthenia gravis severity.
    Abraham A; Breiner A; Barnett C; Katzberg HD; Lovblom LE; Rt MN; Bril V
    Muscle Nerve; 2017 Sep; 56(3):445-448. PubMed ID: 28029691
    [TBL] [Abstract][Full Text] [Related]  

  • 4. IVIG Versus PLEX in the Treatment of Worsening Myasthenia Gravis: What is the Evidence?: A Critically Appraised Topic.
    Dhawan PS; Goodman BP; Harper CM; Bosch PE; Hoffman-Snyder CR; Wellik KE; Wingerchuk DM; Demaerschalk BM
    Neurologist; 2015 May; 19(5):145-8. PubMed ID: 25970838
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Comparison of IVIg and PLEX in patients with myasthenia gravis.
    Barth D; Nabavi Nouri M; Ng E; Nwe P; Bril V
    Neurology; 2011 Jun; 76(23):2017-23. PubMed ID: 21562253
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Surrogate therapeutic outcome measures in patients with myasthenia gravis.
    Zinman L; Baryshnik D; Bril V
    Muscle Nerve; 2008 Feb; 37(2):172-6. PubMed ID: 17918748
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Immunoglobulin treatment versus plasma exchange in patients with chronic moderate to severe myasthenia gravis.
    Rønager J; Ravnborg M; Hermansen I; Vorstrup S
    Artif Organs; 2001 Dec; 25(12):967-73. PubMed ID: 11843764
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The quantitative myasthenia gravis score: comparison with clinical, electrophysiological, and laboratory markers.
    Barnett C; Katzberg H; Nabavi M; Bril V
    J Clin Neuromuscul Dis; 2012 Jun; 13(4):201-5. PubMed ID: 22622164
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Predictors of response to immunomodulation in patients with myasthenia gravis.
    Katzberg HD; Barnett C; Bril V
    Muscle Nerve; 2012 May; 45(5):648-52. PubMed ID: 22499090
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Changes in quality of life scores with intravenous immunoglobulin or plasmapheresis in patients with myasthenia gravis.
    Barnett C; Wilson G; Barth D; Katzberg HD; Bril V
    J Neurol Neurosurg Psychiatry; 2013 Jan; 84(1):94-7. PubMed ID: 23154126
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Importance of neuromuscular "jitter" under stimulation in the diagnosis of myasthenia gravis].
    Durand MC; Goulon-Goeau C; Gajdos P
    Neurophysiol Clin; 1997 Dec; 27(6):471-82. PubMed ID: 9488971
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Ocular myasthenia gravis in an academic neuro-ophthalmology clinic: clinical features and therapeutic response.
    Mittal MK; Barohn RJ; Pasnoor M; McVey A; Herbelin L; Whittaker T; Dimachkie M
    J Clin Neuromuscul Dis; 2011 Sep; 13(1):46-52. PubMed ID: 22361625
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A comparison between IVIG and plasma exchange as preparations before thymectomy in myasthenia gravis patients.
    Alipour-Faz A; Shojaei M; Peyvandi H; Ramzi D; Oroei M; Ghadiri F; Peyvandi M
    Acta Neurol Belg; 2017 Mar; 117(1):245-249. PubMed ID: 27530310
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Management of myasthenia gravis.
    Schwendimann RN; Burton E; Minagar A
    Am J Ther; 2005; 12(3):262-8. PubMed ID: 15891271
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Clinical correlates with anti-MuSK antibodies in generalized seronegative myasthenia gravis.
    Evoli A; Tonali PA; Padua L; Monaco ML; Scuderi F; Batocchi AP; Marino M; Bartoccioni E
    Brain; 2003 Oct; 126(Pt 10):2304-11. PubMed ID: 12821509
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Intravenous immunoglobulin for myasthenia gravis.
    Gajdos P; Chevret S; Toyka K
    Cochrane Database Syst Rev; 2008 Jan; (1):CD002277. PubMed ID: 18254004
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A comparison of the effectiveness of intravenous immunoglobulin and plasma exchange as preoperative therapy of myasthenia gravis.
    Jensen P; Bril V
    J Clin Neuromuscul Dis; 2008 Mar; 9(3):352-5. PubMed ID: 18344718
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Cost-minimization analysis comparing intravenous immunoglobulin with plasma exchange in the management of patients with myasthenia gravis.
    Furlan JC; Barth D; Barnett C; Bril V
    Muscle Nerve; 2016 Jun; 53(6):872-6. PubMed ID: 26521889
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Therapy in myasthenia gravis and Lambert-Eaton myasthenic syndrome.
    Newsom-Davis J
    Semin Neurol; 2003 Jun; 23(2):191-8. PubMed ID: 12894384
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Myasthenia gravis: emerging new therapy options.
    Sieb JP
    Curr Opin Pharmacol; 2005 Jun; 5(3):303-7. PubMed ID: 15907918
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.